River Road Asset Management LLC Takes Position in Smith & Nephew plc (NYSE:SNN)

River Road Asset Management LLC purchased a new position in shares of Smith & Nephew plc (NYSE:SNN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,239,187 shares of the medical equipment provider’s stock, valued at approximately $38,588,000. River Road Asset Management LLC owned approximately 0.28% of Smith & Nephew at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. QRG Capital Management Inc. boosted its holdings in Smith & Nephew by 3.5% during the 3rd quarter. QRG Capital Management Inc. now owns 89,013 shares of the medical equipment provider’s stock worth $2,772,000 after acquiring an additional 3,017 shares during the last quarter. US Bancorp DE boosted its holdings in Smith & Nephew by 19.2% during the third quarter. US Bancorp DE now owns 11,167 shares of the medical equipment provider’s stock worth $348,000 after purchasing an additional 1,802 shares during the last quarter. First Trust Direct Indexing L.P. grew its position in Smith & Nephew by 6.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 9,659 shares of the medical equipment provider’s stock worth $301,000 after purchasing an additional 626 shares in the last quarter. BKM Wealth Management LLC increased its stake in Smith & Nephew by 183.3% in the 3rd quarter. BKM Wealth Management LLC now owns 20,057 shares of the medical equipment provider’s stock valued at $625,000 after buying an additional 12,978 shares during the last quarter. Finally, Coerente Capital Management bought a new position in shares of Smith & Nephew during the 3rd quarter worth approximately $202,000. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew Stock Performance

Shares of SNN opened at $25.67 on Tuesday. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $29.87 and a 200-day moving average price of $27.85. Smith & Nephew plc has a 12-month low of $23.65 and a 12-month high of $31.72.

Analyst Ratings Changes

Several brokerages have recently issued reports on SNN. Deutsche Bank Aktiengesellschaft lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Friday. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.